We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
07/8/2018 07:17 | Ian Mckay appointed new CFO from HSBC. | garycook | |
06/8/2018 16:06 | Thx. We are all here to do well; I hope. | alphorn | |
06/8/2018 16:01 | Pharmaceutical - API research, GSK, Pfizer, Abbott Laboratories, now in Regulatory Science. | tradermichael | |
06/8/2018 16:00 | No intention of an argument - too sensitive! You were in biotech, specialities or big pharma for the most part if I may ask? | alphorn | |
06/8/2018 15:57 | Yes, you came across as argumentative - I have worked in the pharmaceutical industry for my whole career, and of course no major change happens overnight. The impact on the pharma industry of Brexit of any kind will not be felt immediately. Anyhow, its not R&D locations that are critical, it is the supply network. | tradermichael | |
06/8/2018 15:53 | I was not picking an argument - you were just too black and white. How long does it take to move some pharma manufacturing for example? How well do you know the industry? btw. you don't need to tell me where it has operations! | alphorn | |
06/8/2018 15:51 | Alphorn - it means that a company of this size has options on how it conducts business - that's what globalisation is all about. E.g. currently Pharma R&D is at Stevenage and Philadelphia Vaccines R&D is at Belgium, Italy and USA. Consumer Healthcare is in 6 locations in Europe and USA | tradermichael | |
06/8/2018 15:31 | We shall also have to wait and see for the post Brexit tax situation. | alphorn | |
06/8/2018 15:29 | Bit OTT there TM. A large part of R&D activities are in the UK (work permits?); Clinical work (Euro Centre moving out of London); Actives produced overseas (Imports); Exports of product(permits); IP (nobody knows) just to name a few. 'of any kind' is not a phrase that I would have used. | alphorn | |
06/8/2018 15:22 | GSK has a significant global presence with commercial operations in more than 150 countries, a network of 86 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China. Simply because it is a UK company does not mean that its operations are vulnerable to Brexit of any kind. | tradermichael | |
06/8/2018 14:35 | Agree with all Garycook says. Buywell - Why would GSK be hard hit with other Pharmers. Surely no Brexit deal would hit sterling and help GSK. Any clarification welcome. Thanks | rsharman | |
06/8/2018 14:10 | Improving outlook With the GlaxoSmithKline share price having risen by 19% since the start of the year, it continues to beat the FTSE 100. More outperformance could be ahead, since the business seems to be heading in the right direction when it comes to its strategy. It has a diverse business model and has resisted calls from some investors to split into different entities. In its current state, it offers a mix of growth potential from its pipeline and consumer brands, as well as defensive characteristics due in part to its diverse range of operations. With GlaxoSmithKline having a dividend yield of around 5.2%, it continues to offer a wide margin of safety. Given that dividends have not risen in recent years, its cover is now at around 1.4. This suggests that dividend growth could restart over the medium term, and this may lead to an improving investment outlook. Although the FTSE 100’s prospects appear to be sound, buying defensive stocks could be a shrewd move. The next bear market may not be too far away, and companies such as GlaxoSmithKline may perform better in more difficult trading conditions than the majority of their index peers. | garycook | |
06/8/2018 13:50 | Agreed Jim Rogers recent record not good. However I don’t know 0f any reliable forcaster So many publications bombard you covering every eventuality and then tell you That they predicted what was coming. | atlantic57 | |
06/8/2018 12:51 | Jim Rodgers did well betting against the BoE but his record since then hasn't been great. He's been in the telegraph a few times and all of his calls have been badly wrong. One swallow doth not make a summer etc. I've sold half my holding here today. Thats about 13% up since I bought them (inc dividends). I struggle to see where the growth is going to come from, and I don't see the markets performing generally over the next few months with the US/China & Brexit issues muddying the waters somewhat. Hopefully will be proved wrong though. | dr biotech | |
06/8/2018 12:45 | @Atlantic, indeed the funny money(AKA QE) has propped up western economies. growth has been anaemic despite the trillions thrown at it. That , in itself, should tell you there are real serious problems. QE being withdrawn, interest rates rising. Double whammy. Wont end well for so many over leveraged people...and for many others used to living beyond their means, the fate will be similar. Concerning times for such heralds in a "Socialist Govt" The appeal of "freebies" is most enticing. No such thing of course as someone,somewhere, is paying. Very worrying times. | fangorn2 | |
06/8/2018 12:36 | A Hard Brexit is going to hurt BIG Pharmas more than most ........... Trump told May to sue the EU ............... It will soon become apparent that article 50 will make the UK electorate see that Trump gave May wise council However as May would not have been employed as Mrs T's tea lady , let alone No 10 sweeper up , she has not the nous to understand that what Trump was passing on was expert legal advice from some of the top USA lawyers , experts at what America does best Sue the @rse of anything they can. In the case of the EU, they deserve to be taken to the cleaners , where May works weekends I believe. | buywell3 | |
06/8/2018 11:55 | Nice rice to recent resistance. On Jim Rogers he has been predicting a crash for as long as I can remember! He also said things would get much worse in the US after 2008 and the Dow has doubled since then! In my book that makes him spectacularly wrong even if it does crash at some point in the future. | tim 3 | |
06/8/2018 11:35 | Ok as it's predicting season ..I'm going for a wet Autumn/Winter ..we had a relatively cold one ..hot summer .. | badtime | |
06/8/2018 11:27 | Graph showing great strength and stellar recovery since February 1250p lows. UBS put out a repeat BUY Recommendation on Friday with their recently increased (30/7) TARGET PRICE of 1700p. Looking good. More to come. ALL IMO. DYOR. QP | quepassa | |
06/8/2018 11:07 | Fangorn that is a good summary I have been expecting a crash for some time but the central bankers have managed to keep the show on the road. I think Trump May fire the fed chief Jerome Powell before the end of the year.Trump has tweeted regularly that he wants a weak dollar so he is on a collision course with Powell who has clearly signalled his intention to raise interest rates. | atlantic57 | |
06/8/2018 10:55 | Nice price action, divi hunters bought the recent dip ..I did. Should eventually show some defensive qualities going fwd. | ny boy | |
06/8/2018 10:53 | @Alphorn, Water,And precious metals imo. Everything else negotiable. :) | fangorn2 | |
06/8/2018 10:47 | Fangorn - maybe; but then the question arises - which asset class to go for? (Within equities Big Pharma may escape somewhat?) | alphorn | |
06/8/2018 10:42 | @Atlantic, Interest rate rises will be biting by may/June next year. As well as that trade war currently simmering in background. 10yr UST's will hit 3.5% Bond bubble finally going to burst. Massively overbought. Going to be a very cold miserable winter as well. | fangorn2 | |
06/8/2018 10:16 | Fangorn if accurate that is priceless Information. How have you arrived at these dates.? Jim Rogers favours 2019. I will go into cash on 30 April 2019:)) | atlantic57 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions